August 13, 2019
Lilly’s Taltz meets endpoints in phase 4 plaque psoriasis test
Eli Lilly’s Taltz met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, testing Taltz versus TREMFYA (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).